drugset / Trial / NCT01939977
Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.
Phase 4
Completed
148 enrolled
Fundación Senefro
AbbVie · collabEffice Servicios Para la Investigacion S.L. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To demonstrate the superiority of paricalcitol treatment at early renal post-transplantation (M6) in the control of iPTH (Intact parathyroid hormone) compared to the use of vitamin D nutritional supplements (calcifediol) in patients with renal transplantation.
Timeline
- Start
- 2014-01
- Primary completion
- 2015-09
- Completion
- 2015-12
Outcome
Met primary endpoint
registry analysis (superiority test); Paricalcitol vs Calcifediol; p = 0.0083; Chi-squared NCT01939977 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Calcifediol | Unknown | — | Oral |
| Subject | Paricalcitol | Other / unclassified | — | Oral |